INO-1001

DRUG3 trials

Sponsors

Inotek Pharmaceuticals Corporation, Genentech, Inc.

Conditions

Acute Myocardial InfarctionHeart DiseasesMelanomaPostoperative Complications

Phase 1

A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

TerminatedNCT00272415

Genentech, Inc.Melanoma

Start: 2005-10-31Target: 39Updated: 2009-03-11

Phase 2

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

TerminatedNCT00271167

Inotek Pharmaceuticals CorporationHeart Diseases, Postoperative Complications

Start: 2005-10-31End: 2006-06-30Target: 162Updated: 2015-03-25

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

CompletedNCT00271765

Inotek Pharmaceuticals CorporationAcute Myocardial Infarction

Start: 2004-01-31End: 2006-06-30Target: 40Updated: 2006-11-29